These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32939607)

  • 1. A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
    Doi T; Tajimi M; Mori J; Asou H; Inoue K; Benhadji KA; Naito Y
    Invest New Drugs; 2021 Apr; 39(2):469-476. PubMed ID: 32939607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
    Azaro A; Baldini C; Rodon J; Soria JC; Yuen E; Lithio A; Oakley G; Benhadji KA; Massard C
    Invest New Drugs; 2021 Feb; 39(1):193-201. PubMed ID: 32915419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
    Azaro A; Massard C; Tap WD; Cassier PA; Merchan J; Italiano A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
    Invest New Drugs; 2021 Aug; 39(4):1089-1098. PubMed ID: 33686452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
    Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
    Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
    Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
    Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
    Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
    Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects.
    Yuen E; Posada M; Smith C; Thorn K; Greenwood D; Burgess M; A Benhadji K; Ortega D; Chinchen L; Suico J
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):483-492. PubMed ID: 30539232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
    Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
    Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.
    Aung KL; El-Khoueiry AB; Gelmon K; Tran B; Bajaj G; He B; Chen T; Zhu L; Poojary S; Basak S; Qi Z; Spreafico A; Fischer BS; Desai J
    Invest New Drugs; 2018 Dec; 36(6):1026-1036. PubMed ID: 29637471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
    Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
    J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
    Doi T; Hewes B; Kakizume T; Tajima T; Ishikawa N; Yamada Y
    Cancer Sci; 2018 Jan; 109(1):193-198. PubMed ID: 29059492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
    Kondo S; Katsuya Y; Yonemori K; Komuro K; Sugeno M; Kawata T; Ghiorghiu D; Meulendijks D; Yamamoto N
    Cancer Treat Res Commun; 2024; 39():100809. PubMed ID: 38593512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.
    Iwasa S; Yamamoto N; Shitara K; Tamura K; Matsubara N; Tajimi M; Lin AB; Asou H; Cai Z; Inoue K; Shibasaki Y; Saito K; Takai H; Doi T
    Cancer Sci; 2018 Oct; 109(10):3216-3223. PubMed ID: 30040168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
    Pant S; Jones SF; Kurkjian CD; Infante JR; Moore KN; Burris HA; McMeekin DS; Benhadji KA; Patel BKR; Frenzel MJ; Kursar JD; Zamek-Gliszczynski MJ; Yuen ESM; Chan EM; Bendell JC
    Eur J Cancer; 2016 Mar; 56():1-9. PubMed ID: 26798966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.